Biodexa Pharmaceuticals (BDRX) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs, including GIST, FAP, NMIBC, and T1D.

• Pipeline includes eRapa (licensed from Emtora Biosciences), MTX240 (licensed from Otsuka), and tolimidone, with ongoing Phase 2 and Phase 3 studies.

• Recent strategic shift includes deprioritizing MTX110 and closing the Cardiff laboratory, ceasing investment in drug delivery technologies.

Financial performance and metrics

• As of December 31, 2025, cash and cash equivalents were £8.5 million, with pro forma as-adjusted cash of £10.6 million after recent offerings.

• Total equity as of December 31, 2025 was £11.4 million, increasing to £13.5 million pro forma as-adjusted.

• Recent offerings raised gross proceeds of approximately $0.8 million (Registered Direct Offering), $1.7 million (Warrant Inducement), and $1.0 million (July 2026 Private Placement).

Use of proceeds and capital allocation

• No proceeds will be received from the resale of shares by selling shareholders; proceeds from warrant exercises for cash will be used by the company.

• Funds are intended to support ongoing clinical development and business expansion; no dividends are planned as earnings will be retained.